Physician profile

Hiten C Patel

Psychiatry · Royal Oak, MI

NPI 1972585248

$731.25

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$137.55

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Sunovion Pharmaceuticals INC. $175.49 2019-2020
Teva Pharmaceuticals USA, INC. $154.52 2020
Neurocrine Biosciences, INC. $136.73 2019-2023 Ingrezza
Vanda Pharmaceuticals INC. $129.86 2020-2023 Hetlioz, Fanapt
Alkermes, INC. $50.32 2023 Lybalvi
Abbvie INC. $28.58 2023
Allergan, INC. $21.58 2019
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $20.93 2021
Janssen Pharmaceuticals, INC $13.24 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Hiten C Patel

$731.25

in general payments reported 2019-2025

Years
2019-2023
Top company
Sunovion Pharmaceuticals INC.

https://glasscript.com/doctor/362160/hiten-c-patel

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.